SBRT for elderly oligometastatic patients as a feasible, safe and effective treatment opportunity.
Elderly
Frailty
Older age
Oligometastases
Stereotactic body radiotherapy
Journal
Clinical & experimental metastasis
ISSN: 1573-7276
Titre abrégé: Clin Exp Metastasis
Pays: Netherlands
ID NLM: 8409970
Informations de publication
Date de publication:
10 2021
10 2021
Historique:
received:
04
07
2021
accepted:
30
08
2021
pubmed:
7
9
2021
medline:
24
11
2021
entrez:
6
9
2021
Statut:
ppublish
Résumé
The constantly increasing life expectancy is raising the issue of treating oncological older patients, who were traditionally candidates to best supportive care or palliative treatments. Several literature data support SBRT in the treatment of the oligometastatic patient as a potentially curable therapeutic option. However, data on older patients are lacking. This study presents the outcomes of a cohort of 61 oligometastatic patients over the age of 80 years who received SBRT, that was proposed to all patients with a minimum Karnofsky Performance Status ≥ 70 and a life expectancy of at least 6 months, with up to five oligometastatic lesions. Radiotherapy was delivered in 3-10 fractions with VMAT-IGRT technique. Toxicity was retrospectively collected according to CTCAE v4.0. Data were retrospectively collected and analyzed. Univariate and multivariate analysis were performed for assessing any potential predictive factor for clinical outcomes. A total of 90 oligometastases were treated in 61 patients with median age 82 years (range, 80-90). The most frequent histology was colorectal cancer (27% of cases). Median follow-up was 20 months (range, 2-63). Local control rates at 1- and 2-years were 98.8% and 88.2%, with colorectal histology being associated with worse LC rates (p = 0.014) at univariate analysis. Progression-free survival rates at 1- and 2-years were 48.6% and 30.5%. Oligorecurrent lesions and single oligometastases were associated with better PFS rates (respectively, p = 0.04 and p = 0.011). Overall survival rates were 75% and 60.5%, polymetastatic spread being predictive of worse survival outcomes at multivariate analysis (p = 0.012). No G2 or higher adverse events were recorded. Our study supports the role of SBRT for the treatment of elderly oligometastatic patients, highlighting the possibility to further explore this therapeutic option in the management of older oncological patients.
Identifiants
pubmed: 34487288
doi: 10.1007/s10585-021-10122-x
pii: 10.1007/s10585-021-10122-x
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
475-481Informations de copyright
© 2021. The Author(s), under exclusive licence to Springer Nature B.V.
Références
Dalwadi SM, Szeja SS, Bernicker EH, Butler EB, Teh BS, Farach AM (2018) Practice patterns and outcomes in elderly stage I non-small-cell lung Cancer: a 2004 to 2012 SEER analysis. Clin Lung Cancer 19(2):e269–e276. https://doi.org/10.1016/j.cllc.2017.11.004
doi: 10.1016/j.cllc.2017.11.004
pubmed: 29208356
Cuccia F, Mortellaro G, Mazzola R, Donofrio A, Valenti V, Tripoli A, Matranga D, Lo Casto A, Failla G, Di Miceli G, Ferrera G (2020) Prognostic value of two geriatric screening tools in a cohort of older patients with early stage Non-Small Cell Lung Cancer treated with hypofractionated stereotactic radiotherapy. J Geriatr Oncol 11(3):475–481. https://doi.org/10.1016/j.jgo.2019.05.002
doi: 10.1016/j.jgo.2019.05.002
pubmed: 31122872
Niedersüß-Beke D, Orlinger M, Falch D, Heiler C, Piringer G, Thaler J, Hilbe W, Petzer A, Rumpold H (2021) Clinical effectiveness of oncological treatment in metastatic colorectal cancer is independent of comorbidities and age. Cancers (Basel) 13(9):2091. https://doi.org/10.3390/cancers13092091 (PMID:33925931;PMCID:PMC8123394)
doi: 10.3390/cancers13092091
Rosko AE, Steer C, Chien LC, Zittel J, Artz A, Chow S, Plotkin E, Dale W, Elias R, Chapman AE (2021) The Cancer and Aging Research Group (CARG) infrastructure: the clinical implementation core. J Geriatr Oncol S1879–4068(21):00086–00092. https://doi.org/10.1016/j.jgo.2021.04.001
doi: 10.1016/j.jgo.2021.04.001
Cuccia F, Fiorentino A, Corrao S, Mortellaro G, Valenti V, Tripoli A, De Gregorio G, Serretta V, Verderame F, Ognibene L, Lo Casto A, Ferrera G (2020) Moderate hypofractionated helical tomotherapy for prostate cancer in a cohort of older patients: a mono-institutional report of toxicity and clinical outcomes. Aging Clin Exp Res 32(4):747–753. https://doi.org/10.1007/s40520-019-01243-1
doi: 10.1007/s40520-019-01243-1
pubmed: 31267377
Fiorentino A, Gregucci F, Mazzola R, Figlia V, Ricchetti F, Sicignano G, Giajlevra N, Ruggieri R, Fersino S, Naccarato S, Massocco A, Corradini S, Alongi F (2019) Intensity-modulated radiotherapy and hypofractionated volumetric modulated arc therapy for elderly patients with breast cancer: comparison of acute and late toxicities. Radiol Med 124(4):309–314. https://doi.org/10.1007/s11547-018-0976-2
doi: 10.1007/s11547-018-0976-2
pubmed: 30547358
Gogineni E, Rana Z, Vempati P, Karten J, Sharma A, Taylor P, Pereira L, Frank D, Paul D, Seetharamu N, Ghaly M (2020) Stereotactic body radiotherapy as primary treatment for elderly and medically inoperable patients with head and neck cancer. Head Neck 42(10):2880–2886. https://doi.org/10.1002/hed.26342
doi: 10.1002/hed.26342
pubmed: 32691496
Cheng KK, Lim EY, Kanesvaran R (2018) Quality of life of elderly patients with solid tumours undergoing adjuvant cancer therapy: a systematic review. BMJ Open 8(1):e018101. https://doi.org/10.1136/bmjopen-2017-018101
doi: 10.1136/bmjopen-2017-018101
pubmed: 29371271
pmcid: 5786145
Belgioia L, Desideri I, Errico A, Franzese C, Daidone A, Marino L, Fiore M, Borghetti P, Greto D, Fiorentino A, AIRO Giovani Italian Association of Radiation Oncology-Young Members Working Group (2019) Safety and efficacy of combined radiotherapy, immunotherapy and targeted agents in elderly patients: a literature review. Crit Rev Oncol Hematol 133:163–170. https://doi.org/10.1016/j.critrevonc.2018.11.009
doi: 10.1016/j.critrevonc.2018.11.009
pubmed: 30661652
Gregucci F, Fiorentino A, Corradini S, Figlia V, Mazzola R, Ricchetti F, Ruggieri R, Alongi F (2019) Linac-based radiosurgery or fractionated stereotactic radiotherapy with flattening filter-free volumetric modulated arc therapy in elderly patients: A mono-institutional experience on 110 brain metastases. Strahlenther Onkol 195(3):218–225. https://doi.org/10.1007/s00066-018-1405-0
doi: 10.1007/s00066-018-1405-0
pubmed: 30478669
Mazzola R, Figlia V, Rigo M, Cuccia F, Ricchetti F, Giaj-Levra N, Nicosia L, Vitale C, Sicignano G, De Simone A, Naccarato S, Ruggieri R, Alongi F (2020) Feasibility and safety of 1.5T MR-guided and daily adapted abdominal-pelvic SBRT for elderly cancer patients: geriatric assessment tools and preliminary patient-reported outcomes. J Cancer Res Clin Oncol 146(9):2379–2397. https://doi.org/10.1007/s00432-020-03230-w
doi: 10.1007/s00432-020-03230-w
pubmed: 32372146
Sahgal A, Chang JH, Ma L, Marks LB, Milano MT, Medin P, Niemierko A, Soltys SG, Tomé WA, Wong CS, Yorke E, Grimm J, Jackson A (2019) Spinal cord dose tolerance to stereotactic body radiation therapy. Int J Radiat Oncol Biol Phys S0360–3016(19):33862–33863. https://doi.org/10.1016/j.ijrobp.2019.09.038
doi: 10.1016/j.ijrobp.2019.09.038
American Association of Physicists in Medicine (AAPM) Task Group 101 report
Moraes FY, Chen X, Yan M et al (2020) Evolving role of stereotactic body radiation therapy in the management of spine metastases: defining dose and dose constraints. Neurosurg Clin N Am 31(2):167–189. https://doi.org/10.1016/j.nec.2019.12.001
doi: 10.1016/j.nec.2019.12.001
pubmed: 32147009
Hanna GG, Murray L, Patel R et al (2018) UK consensus on normal tissue dose constraints for stereotactic radiotherapy. Clin Oncol 30(1):5–14
doi: 10.1016/j.clon.2017.09.007
Pollom EL, Chin AL, Diehn M, Loo BW, Chang DT (2017) Normal tissue constraints for abdominal and thoracic stereotactic body radiotherapy. Semin Radiat Oncol 27(3):197–208. https://doi.org/10.1016/j.semradonc.2017.02.001
doi: 10.1016/j.semradonc.2017.02.001
pubmed: 28577827
Lancia A, Ingrosso G, Carosi A, Bottero M, Cancelli A, Turturici I, Ponti E, Santoni R (2019) Oligometastatic cancer in elderly patients: the “blitzkrieg” radiotherapy approach: SBRT in oligometastatic elderly patients. Aging Clin Exp Res 31(1):109–114. https://doi.org/10.1007/s40520-018-0937-6
doi: 10.1007/s40520-018-0937-6
pubmed: 29594874
Hutchins LF, Unger JM, Crowley JJ, Coltman CA Jr, Albain KS (1999) Underrepresentation of patients 65 years of age or older in cancer-treatment trials. N Engl J Med 341(27):2061–2067. https://doi.org/10.1056/NEJM199912303412706
doi: 10.1056/NEJM199912303412706
pubmed: 10615079
Liuu E, Canoui-Poitrine F, Tournigand C et al (2014) Accuracy of the G-8geriatric-oncology screening tool for identifying vulnerable elderly patients with cancer according to tumour site: the ELCAPA-02 study. J Geriatr Oncol 5:11–9. https://doi.org/10.1016/j.jgo.2013.08.003
doi: 10.1016/j.jgo.2013.08.003
pubmed: 24484713
Maebayashi T, Ishibashi N, Aizawa T, Sakaguchi M, Saito T, Kawamori J et al (2018) Significance of stereotactic body radiotherapy in older patients with early stage non-small cell lung cancer. J Geriatr Oncol 9:594–599
doi: 10.1016/j.jgo.2018.03.005
Schulkes KJG, Souwer ETD, van Elden LJR, Codrington H, van der Sar-van der Brugge S, Lammers JJ, et al (2017) Prognostic value of geriatric 8 and identification of seniors at risk for hospitalized patients screening tools for patients with lung cancer. Clin Lung Cancer 18: 660–666.e1
Yokom DW, Alibhai SMH, Sattar S, Krzyzanowska MK, Puts MTE (2018) Geriatric oncology screening tools for CGA-based interventions: results from a phase II study of geriatric assessment and management for older adults with cancer. J Geriatr Oncol 9:683–686
doi: 10.1016/j.jgo.2018.03.001
Rosenbluth RG (2012) Geriatric oncology. Clin Geriatr Med 28:1
doi: 10.1016/j.cger.2011.09.001
Scorsetti M, Clerici E, Navarria P, D’Agostino G, Piergallini L, De Rose F, Ascolese A, Tozzi A, Iftode C, Villa E, Comito T, Franzese C, Mancosu P, Tomatis S, Cozzi L (2015) The role of stereotactic body radiation therapy (SBRT) in the treatment of oligometastatic disease in the elderly. Br J Radiol 88(1053):20150111. https://doi.org/10.1259/bjr.20150111
doi: 10.1259/bjr.20150111
pubmed: 26183933
pmcid: 4743569
Kreinbrink P, Blumenfeld P, Tolekidis G, Sen N, Sher D, Marwaha G (2017) Lung stereotactic body radiation therapy (SBRT) for early-stage non-small cell lung cancer in the very elderly (≥80years old): extremely safe and effective. J Geriatr Oncol 8:351–355
doi: 10.1016/j.jgo.2017.07.002
Osti MF, Agolli L, Valeriani M, Reverberi C, Bracci S, Marinelli L, De Sanctis V, Cortesi E, Martelli M, De Dominicis C, Minniti G, Nicosia L (2018) 30 Gy single dose stereotactic body radiation therapy (SBRT): Report on outcome in a large series of patients with lung oligometastatic disease. Lung Cancer. 122:165–170. https://doi.org/10.1016/j.lungcan.2018.06.018
doi: 10.1016/j.lungcan.2018.06.018
pubmed: 30032826
Videtic GMM, Woody NM, Reddy CA, Stephans KL (2017) Never too old: a single-institution experience of stereotactic body radiation therapy for patients 90 years and older with early stage lung cancer. Pract Radiat Oncol 7:e543–e549
doi: 10.1016/j.prro.2017.06.011
Zelefsky MJ, Yamada Y, Greco C, Lis E, Schöder H, Lobaugh S, Zhang Z, Braunstein S, Bilsky MH, Powell SN, Kolesnick R, Fuks Z (2021) Phase 3 multi-center, prospective, randomized trial comparing single-dose 24 Gy radiation therapy to a 3-fraction SBRT regimen in the treatment of oligometastatic cancer. Int J Radiat Oncol Biol Phys 110(3):672–679. https://doi.org/10.1016/j.ijrobp.2021.01.004
doi: 10.1016/j.ijrobp.2021.01.004
pubmed: 33422612
pmcid: 33422612